Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A22.

Figure A22

Risk ratio for breakthrough acute respiratory infection (ARI) after the delivery of respiratory syncytial virus (RSV) vaccine (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0, 95% CI 0.0 to 0.731; Q = 0.79, p = 0.675) in follow up studies [48,61,85].